Amer Zeidan, Chief, Division of Hematologic Malignancies at Yale University, shared on LinkedIn:
“Answering Clinician Questions About Anemia in Lower-Risk Myelodysplastic Syndromes: Community-Based Strategies to Enhance Long-Term Efficacy.”
Other articles about Myelodysplastic Syndrome on OncoDaily.